Moody National Bank Trust Division Has $1.46 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Moody National Bank Trust Division decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,760 shares of the biopharmaceutical company’s stock after selling 592 shares during the period. Moody National Bank Trust Division’s holdings in Gilead Sciences were worth $1,456,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. nVerses Capital LLC bought a new stake in shares of Gilead Sciences during the third quarter valued at approximately $25,000. Valued Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares in the last quarter. Cedar Wealth Management LLC boosted its position in shares of Gilead Sciences by 51.6% during the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 160 shares in the last quarter. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences in the second quarter worth about $33,000. Finally, Quarry LP bought a new position in Gilead Sciences during the second quarter worth about $43,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GILD has been the subject of a number of recent research reports. Piper Sandler increased their target price on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Robert W. Baird upped their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Truist Financial lifted their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a report on Friday, November 8th. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Finally, Morgan Stanley raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $87.00 to $113.00 in a report on Friday. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $97.96.

Insider Buying and Selling

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares of the company’s stock, valued at $9,113,308.50. This trade represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 453,734 shares of company stock valued at $41,902,086. 0.16% of the stock is owned by company insiders.

Gilead Sciences Trading Up 0.1 %

NASDAQ GILD opened at $89.94 on Tuesday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company has a market capitalization of $112.09 billion, a PE ratio of 999.33, a P/E/G ratio of 2.24 and a beta of 0.18. The stock has a 50-day simple moving average of $91.94 and a 200 day simple moving average of $83.54.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period last year, the company posted $2.29 EPS. Research analysts forecast that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.42%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.